ASSA ABLOY Australia is proud to have their Lockwood branded products specified in The Chris O'Brien Lifehouse at RPA; a ground breaking facility, that will transform cancer treatment for Australians in an environment thriving on discovery, research and uncompromising care.
ASSA ABLOY Australia can attribute its involvement in the build of this world-class cancer treatment and research facility (Chris O’Brien Lifehouse) not only to its strong [sales representative - customer] relationship with builder, Brookfield Multiplex, but also to their ability to offer the customer a full hardware solution; designed to fit within budget and design restraints.
ASSA ABLOY staff went to great lengths to secure the project including independent testing on door closers for compliance to the DDA (Disability Discrimination Act); in order for the client to have the specified oversized height doors installed.
The $142 million project, in New South Wales, Australia, will build on the reputation of Royal Prince Alfred Hospital and integrate clinical care, research and education, creating opportunities for innovative discoveries, compassionate holistic care and better outcomes for patients living with cancer. The facility has been named after Chris O’Brien (3 Jan 1952 - 4 June 2009) a man of leadership, vision and courage. He inspired people, both through his work as a cancer specialist and through his own three-year battle with an aggressive brain tumour. Chris O’Brien “envisioned a centre where patients would no longer have to navigate their way through the complexities of modern cancer care alone,” says Professor Michael Boyer, Chief Clinical Office at The Chris O’Brien Lifehouse at RPA.
The nine storey, 43,500 square metre facility is due for completion in mid 2013 and includes the following Lockwood products: Pentagon mortice locks, 1800/70 series DDA compliant furniture, 7714/7726, 985 series, 2516EMC closers, Padde electronic strikes, V locks, 8002 auto operators and MT5+ keying, to name a few.